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Abstract 
Purpose: To prepare and evaluate sustained-release ketoprofen implants for prolonged drug release 
and activity.  
Methods: Ketoprofen implants were prepared with poly (lactic-co-glycolic acid) (PLGA) and chitosan in 
the form of tablets. The implants were analyzed for drug loading, thickness, hardness, swelling, in vitro 
drug release, as well as in vivo analgesic and anti-inflammatory activities. 
Results: The implants were round, smooth in appearance, uniform in thickness and showed no cracks 
or physical defects on the surface. Their friability was < 1 % while drug content ranged from 89.98 ± 
2.06 to 92.95 ± 1.65 %. In vitro drug release ranged from 70.23 to 92.04 % at the end of 5 days. 
Implants containing higher amounts of PLGA produced the highest swelling (40.24 ± 1.08 %). Implant 
IKT3 showed maximum analgesic activity (7.75 ± 1.00 s) and shortest time of maximum analgesia (2.5 
h) in hot plate method. Inhibition of rat paw edema for IKT1, IKT2 and IKT3 was 79.95, 69.98 and 82.24 
%, respectively, after 24 h.  
Conclusion: Ketoprofen-loaded implant IKT3 (4:4:2 ratio of PLGA, chitosan and ketoprofen) provides 
relatively quick onset and prolonged duration of analgesic effect. Thus, ketoprofen implants have a 
potential for development into therapeutic products for prolonged management of pain and inflammation 
in osteoarthritis.  
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Osteoarthritis is a disorder involving 
degeneration of articulate cartilage in the joints. It 
causes moderate-to-severe joint pain and 
reduced motion due to breakdown and the loss 
of cartilage in one or more joints [1,2]. Put more 
precisely, osteoarthritis is not a disease, but 
rather it is a common complex disorder with 
multiple risk factors (like knee/hip osteoarthritis, 
obesity, high bone density, aging, and reduced 
muscle strength). Osteoarthritis has been 
reported to affect more than 20 million individuals 
in the USA alone; it is the foremost cause of 
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mortality in the aged population (more than 70 
years of age) and costs the USA over US$100 
billion per annum [3-6].  
 
Osteoarthritis may be of the primary or 
secondary type. Increased stress on major 
weight-bearing joints or on weakened joints 
causes primary osteoarthritis. In general it affects 
the knees, finger joints, cervical and lumbar 
spine and the big toe. On the other hand, 
secondary osteoarthritis generally results from 
either chronic or any sudden injury (due to 
trauma, septic arthritis, metabolic disorder or 
developmental disorders) to a joint. The most 
common symptom of osteoarthritis is pain in the 
affected joints [7,8]. 
 
To manage pain and inflammation in 
osteoarthritis, non-steroidal anti-inflammatory 
drugs (NSAIDs) are frequently prescribed. 
However, prolonged use of NASIDs is associated 
with many side effects which may range from 
gastric discomfort (ulcers, irritation, and 
bleeding), to kidney failure and cardiac side 
effects (cardiac arrest and stroke) [9-11].  
 
An implant may be defined as a polymeric 
system which is prepared to fill/ replace/support 
or enhance a biological structure and/or to 
provide prolonged drug delivery. A subcutaneous 
drug implant may be one of the most practical 
approaches for delivering drugs in the 
microenvironment of the affected joint/bones so 
as to achieve continuous and prolonged drug 
administration. Biodegradable implants prepared 
with poly glycolic acid (PGA), poly L-lactic acid 
(PLLA), and polylactic co-polymer have been 
investigated for use in small fingers and toes in 
treating osteoarthritis and rheumatoid arthritis 
[12-14]. The shape and size of the implant may 
vary depending on the site of administration. The 
implant may be pin, rod, cube, film, sponge or 
tablet-shaped. 
 
Ketoprofen (chemically known as 2(3-benzoyl 
phenyl) propionic acid is a very widely prescribed 
NSAID for the treatment of RA and OA. 
Ketoprofen inhibits cyclooxygenase -1 (COX-1) 
and COX-2, which are enzymes that inhibit the 
production of prostaglandins. Ketoprofen has a 
short biological half-life (1 - 3 h), and its chronic 
use is associated with gastric irritation / bleeding 
[15]. The present study was aimed at developing 
biodegradable implants loaded with ketoprofen 
for prolonged and localized drug release for 
improved analgesic and anti-inflammatory 
effects. The prepared implants were analyzed for 
drug loading, thickness, hardness, swelling, drug 






Ketoprofen, PLGA, and chitosan (75 % 
deacylated) were purchased from Sigma Aldrich, 
Japan. 
 
Preparation of implants  
 
Direct compression method was used to prepare 
ketoprofen implant tablets. Three formulations of 
implant tablets (IKT1, IKT2 and IKT3) were 
prepared by using PLGA, chitosan and 
ketoprofen as biodegradable polymers at the 
ratios of 5:3:2, 3:5:2 and 4:4:2, respectively at 
room temperature.  A total of 100 mg was mixed 
and kept in a cylinder of diameter 10 mm. 
Tableting was effected by applying a constant 
pressure (50 kg/cm2) for 10 sec using hand press 
single punch machine. All the implant tablets 
were sterilized by gaseous sterilization method 





The thickness of all formulations of implant 
tablets was measured at three different locations 
with the help of screw gauge (n = 3). Hardness 
was tested by using Monsanto hardness tester 
(US). Twenty tablets of each batch were 
evaluated for weight variation (WV) [16]. 
Individual and average weights were calculated. 
Weight variation (WV) was determined using Eq 
1. 
 
 ……………….. (1) 
 
where Wt is total weight of 20 tablets, and Wi is 
the sum of individual weight of 20 tablets. 
 
The friability test was done by placing ten tablets 
(pre-weighed) in a friabilator. The friabilator was 
rotated at a speed of 25 rpm for 4 min. Then the 
tablets were taken out, dusted and again 
weighed. Friability (F) was calculated as in Eq 2. 
 
 ……………. (2) 
 
where Wo was the initial weight (before rotation), 
and Wt was the final weight (after rotation). 
 
For the estimation of drug loading, implant tablet 
(n = 3) was dissolved in methanol (100 ml) with 
continuous stirring on a magnetic stirrer (400 
rpm; temperature 37 ± 1 oC) for 4 h. The 
resultant solution was analyzed 
spectrophotometrically for drug content. 




The morphologies of the surfaces of the implants 
were studied using scanning electron microscopy 
(SEM). The implants were subjected to SEM 
(JEOL, model no.5600, Japan) after hydration 
with phosphate-buffered saline, pH 7.4 for 1 h. 
 
In vitro drug release studies 
 
In vitro drug release studies on the ketoprofen 
implants were carried out in 100 ml bottle (5 cm 
in inner diameter, and 11 cm in height) 
containing phosphate-buffered saline (PBS, pH 
7.4) at a temperature of 37 °C ± 1 oC. The bottle 
was kept on the magnetic stirrer and held in 
place with the help of burette stand. Aliquots (3 
ml) were taken out at different time points (up to 
5 days), and were immediately replaced each 
time with an equal volume of fresh, pre-warmed 
medium. The withdrawn samples were analyzed 
spectrophotometrically at 256 nm. 
 
Swelling and polymer erosion studies 
 
After 120 h of the drug release study, the wet 
weight and dried weight of the implant tablets 
were determined. The amounts of water 
absorbed and the amount of polymer eroded 
were calculated and expressed as percentage 
swelling. 
 




Male Wistar rats (150-225 g, aged about 4 
weeks) were used for the study. They were 
housed in cages in standard conditions with food 
and water ad libitum. The rats were used after a 
resting period of 2 days post-procurement. The 
protocols of the animal study were approved by 
the Animal Ethical Committee of Sichuan 
University, Chengdu (approval no. 2016; 015) 
and were performed according to the guidelines 
2010/63/EU on the handling of animals used for 
scientific purposes [17]. 
 
In vivo analgesic activity  
 
The rats were divided into five groups (6 rats per 
group) viz: control, standard and 3 test groups 
(one each for one single type of formulation). The 
rats were put on a hot plate analgesiometer (MK-
350 D, Japan) maintained at 50 ± 1 °C. The 
three types of implant tablets were surgically 
placed subcutaneously (1.0 mg/kg body weight) 
on the shaved dorsal surface of the rats in the 
respective test groups 30 min before the 
beginning of the test. Rats in the control group 
received blank implants while the standard group 
received oral ketoprofen suspension at the same 
dose. The time it took the rats to start of jumping 
or licking their forepaws was determined as 
reaction time. The maximum response (MR), 
time of the maximum response (TMR) and the 
duration of drug action (DA) were recorded. 
 
In vivo anti-inflammatory activity 
 
The anti-inflammatory activity (in vivo) was 
assessed against carrageenan-induced edema in 
hind paw (using carrageenan) of the rats. One 
control, one standard and three test groups were 
prepared. The hind paw volume of each rat was 
measured for all rats before treatment, using 
mercury plethysmometer. The control group 
received blank implants, while the standard 
group received diclofenac (1.0 mg/kg, p. o.). Rats 
in the test groups received implants (1.0 mg/kg, 
s. c.) which were surgically administered. After 1 
h of implant administration, hind paw edema was 
induced by  injecting  0.1 mL of 1 % w/v aqueous 
suspension of carrageenan  in the right hind 
paws of the rats. The percent inhibition of edema 
relative to the controls was studied. Inhibition of 
edema (H) was calculated using Eq 3.  
 
 ……….. (3) 
 
where Ec is % edema in control  and Et is % 




The results are presented as mean ± standard 
deviation (SD). Statistical analysis was 
performed by ANOVA using GraphPad Prism© 
4.0. Values of p < 0.05 were considered to be 




The physical properties of the three ketoprofen 
implants such as drug content, thickness, weight 
uniformity, hardness and friability are shown in 
Table 1. 
 
Physicochemical characteristics of the 
implants 
 
The implant tablets were round, smooth in 
appearance, uniform in thickness and showed no 
cracks or physical defects on the surface. The 
friability was below 1 %, and the drug content 
ranged from 89.98 ± 2.06 to 92.95 ± 1.65 %. The 
implant tablets absorbed water three times their 
weight before drug release. Hardness value was 
intermediate for IKT1 implants. The surface 
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morphology of the implant tablets studied by 











Figure 1: Scanning electron micrographs of the 
hydrated surface of the implants: (a) IKT1; (b) IKT2; 
(c) IKT3 
 
In vitro drug release 
 
Results from in vitro drug release studies showed 
cumulative drug release of 70.23, 89.24, and 
92.04 % for IKT1, IKT2 and IKT3, respectively at 
the end of 5 days (Figure 2).  
 
 
Figure 2: In vitro release of ketoprofen in phosphate 
buffered saline (pH 7.4) from implants IKT1 (♦), IKT2 
(□), and IKT3 (▲) 
 
In vivo analgesic and anti-inflammatory 
activities 
 
The prepared implants showed very significant in 
vivo analgesic and anti-inflammatory activities 
(Table 2). The best analgesic activity was 
produced by IKT3.  
 
Table 2: In vivo analgesic activity of ketoprofen SR 
implants  
 






IKT1 7.25±1.25 2.5 >24 
IKT2 5.50±1.25  2.75 >24 




1.25±0.50 3.0 8 
aValues are mean ± SD (n = 6); MR = maximum 
analgesic response; TMR= time of maximum 
analgesic response; DA = duration of analgesic action 
 














IKT1 3.24± 0.53 5.0±0.03 4.7±0.034 0.84±0.05 92.95± 1.65 40.24±1.08 
IKT2 3.40± 0.02 5.2±0.02 5.0±0.012 0.77±0.02 89.98± 2.06 28.70±0.02 
IKT3 3.30± 0.32 4.5±0.01 4.8±0.001 0..78±0.02 90.74± 1.31 31.4±1.01 
 
On the other hand, there was no appreciable 
difference between the anti-inflammatory 
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activities of IKT1 and IKT3 implants, although 
they showed better activity than IKT2 or the 
standard (Figure 3). 
 
 
Figure 3: In vivo anti-inflammatory activity in 
carrageenan-induced rat paw edema of the ketoprofen 
sustained-release implants: IKT 1 (♦), IKT2 (□), IKT3 
(◊), Standard (×) 
 
Rat paw edema was inhibited 79.95, 69.98 and 
82.24 % by IKT1, IKT2 and IKT3, respectively at 
the end of 24 h, while 64.45% inhibition was 
exhibited by the standard. The IKT3 implant 
showed longer inhibitory activity than any of the 




Implants are drug delivery systems which provide 
the most intimate and direct contact of the drug 
at the site of action. Localized high concentration 
of drug is very effective in RA and OA [18-21]. In 
the present study, the implants of ketoprofen 
were prepared with PLGA and chitosan for the 
prolonged drug release and effective analgesia 
and anti-inflammatory effect in osteoarthritis. 
 
The implants containing PLGA in larger 
proportion (IKT1) showed high swelling, high 
drug content and high friability, while the implant 
with equal ratio of the polymers (IKT3) showed 
rougher surface than IKT2 or IKT1. The rough 
surface is a quality expected to pave way for 
better drug release. The implants showed good 
qualities. Good swelling is an essential feature 
for the slow release of drug from an implant. The 
selection of polymer, and the amount of polymer 
play a vital role in swelling. Polymeric chains 
generally need to be unfolded for easy drug 
diffusion out of the polymeric matrix of the 
implant. The implant IKT1 containing higher 
amount of PLGA showed the best swelling. It 
was observed that in vitro release showed 
improved drug release with matrix diffusion 
mechanism (assisted by the swelling of the 
polymeric matrix). Thus, the formulation which 
showed better swelling exhibited more prolonged 
drug release [19-22].  It was evident that due to 
better swelling, the drug release was higher with 
IKT1and IKT3 than with IKT2. This might be due 
to the presence of PLGA in high proportion. 
 
In the in vitro analgesic activity, IKT3 showed the 
best analgesic response and the shortest time of 
maximum analgesic response. The ketoprofen 
implants delayed reaction time on the hot plate 
test. The ketoprofen implants were effective at 1 
mg/kg with significantly increased hot-plate 
latency, and their anti-inflammatory effects were 
very effective with long duration of action. 
However, the IKT3 implant provided relatively 
quick onset of action with prolonged duration due 
to its better swelling as well as the prolonged 
drug release. Results from various studies 
indicate effective and prolonged drug delivery 
from polymeric implants in orthopaedics [22-25]. 
The anti-inflammatory activity model of 
carrageenan-induced inflammation showed that 
IKT2 was well balanced in composition, and the 
best-suited preparation for relatively fast onset of 




The findings of this study that the ketoprofen-
loaded implant IKT3 (4:4:2 ratio of PLGA, 
chitosan and ketoprofen) demonstrate quick 
onset and prolonged duration of action. Thus, 
these implants possess potentials for therapeutic 
use in the management of osteoarthritis, but 
extensive preclinical and clinical studies need to 
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